跳至主要内容
临床试验/NCT00432081
NCT00432081已完成3 期

Effect of Indomethacin on the Progression of Alzheimer's Disease

Radboud University Medical Center2 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2000年5月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
160
试验地点
2
主要终点
Score on the Cognitive subscale of the Alzheimer's Disease Assessment Scale at 12 months.

研究概览

简要总结

The purpose of this study is determine whether indomethacin is able to retard disease progression in patients with mild to moderate Alzheimer's disease.

详细描述

Previous research indicates that inflammation plays a role in the pathogenesis of Alzheimer's disease (AD), and nonsteroidal anti-inflammatory drugs (NSAIDs) may retard the progression of the disease.

Comparison(s): Cognitive decline of patients with mild to moderate AD receiving the NSAID indomethacin, compared to cognitive decline of patients with mild to moderate AD receiving placebo, during a one-year period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
40 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •The patient will satisfy the DSM-IV criteria for dementia of the Alzheimer's type.
  • •The patient will satisfy the NINCDS/ADRDA criteria for the clinical diagnosis of probable Alzheimer's disease (Appendix I).
  • •The severity of dementia for each patient will be quantified by a Mini-Mental State Examination (MMSE) score between 10 and 26 (both inclusive).
  • •The patient is living at home or in a home for the elderly.
  • •The patient has a responsible caregiver who is able to provide information about the patient's functional status.
  • •Written informed consent is obtained from the patient or the legally accepted representative.

排除标准

  • •The patient satisfies the NINDS-AIREN criteria for probable vascular dementia.
  • •A known exaggerated pharmacological sensitivity or allergy to NSAID's.
  • •History of peptic ulceration, gastric surgery or gastrointestinal bleeding.
  • •Current diagnosis of active peptic ulceration.
  • •Current diagnosis of severe and unstable cardiovascular disease.
  • •Current diagnosis of renal failure.
  • •Advanced, severe and unstable disease of any type, other than Alzheimer's disease, that may interfere with primary and secondary variable evaluations, including a medical condition which should be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical or mental status of the patient to a significant degree or put the patient at special risk.
  • •Intake of any of the following concomitant medications: salicylates, coumarin derivatives, ACE-inhibitors, loop diuretics.
  • •Intake of any of the following concomitant medications more than two months immediately prior or during the study: NSAID's, systemic corticosteroids.
  • •Intake of any of the following concomitant medications with a possible effect on cognition: estrogen, deprenyl, vitamin E, neuroleptics, anticholinergics. Patients using stable doses of cholinesterase inhibitors were eligible, with the provision that the dose should not be changed during the study. Cholinesterase inhibitors could not be initiated during the study.
  • •Excessive use of alcohol (more than 5 units per day)
  • •The patient is, either alone or with the aid of a caregiver, not able to reliably take the medication.

结局指标

主要结局

Score on the Cognitive subscale of the Alzheimer's Disease Assessment Scale at 12 months.

次要结局

  • Score on the Noncognitive subscale of the Alzheimer's Disease Assessment Scale at 12 months
  • Score on the Clinician Interview-Based Impression of Change with caregiver input at 12 months
  • Score on the Mini-Mental State Examination at 12 months
  • Score on the Neuropsychiatric Inventory at 12 months
  • Score on the The Interview for Deterioration in Daily living activities in Dementia at 12 months
  • The occurrence of adverse events during 12 months of treatment

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验